NutriBand Inc.

Nutriband Inc. operates as a pharmaceutical development company focused on creating transdermal drug delivery systems with abuse-deterrent properties. The company trades on The Stock Market LLC under its legal name Nutriband Inc. and maintains its website at www.nutriband.com.

The company's primary business centers on developing a portfolio of transdermal pharmaceutical products based on its proprietary AVERSA abuse-deterrent transdermal technology. This technology incorporates aversive agents into transdermal patches to deter abuse and misuse of drugs susceptible to recreational use, particularly opioids and stimulants. The lead product candidate, AVERSA Fentanyl, combines an approved generic fentanyl patch with the AVERSA technology to reduce abuse and misuse of fentanyl patches. The company has expanded its development pipeline to include AVERSA Buprenorphine and AVERSA Methylphenidate, with plans to develop additional abuse-deterrent transdermal products as funding becomes available.

Nutriband operates through two primary subsidiaries that generate revenue. Pocono Pharmaceuticals, acquired in August 2020, operates as Active Intelligence and provides contract manufacturing services for health, wellness, and over-the-counter pharmaceutical customers. 4P Therapeutics, acquired in August 2018, performs contract research and development services for pharmaceutical and medical device customers. These subsidiaries support ongoing operations while the company develops its proprietary pharmaceutical pipeline.

The company maintains manufacturing and operational facilities in North Carolina and Florida, with principal offices located in Orlando, Florida. Nutriband primarily operates and derives revenues in the United States, though it holds an international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, Mexico, Canada, Australia, and China, providing patent coverage through 2035.

The company's regulatory strategy for AVERSA Fentanyl follows the FDA's 505(b)(2) pathway, which allows reference to existing safety data for approved drugs and potentially reduces development timelines. In October 2025, Nutriband completed a Type C meeting with the FDA to obtain feedback on chemistry, manufacturing, and controls plans for AVERSA Fentanyl, with the agency confirming the regulatory pathway and offering continued guidance through development.